Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma DOI Creative Commons
Ying Lu, Zhouyu Wang,

Danmeng Zhang

et al.

Cellular and Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 18, 2024

Glioma is the most common primary malignant brain tumor. Despite significant advances in past decade understanding molecular pathogenesis of this tumor and exploring therapeutic strategies, prognosis patients with glioma remains poor. Accurate diagnosis very important for treatment prognosis. Although gold-standard method prediction tissue biopsy, it still has many limitations. Liquid biopsy can provide information on auxiliary gliomas. In review, we summarized application cell-free DNA (cfDNA) circulating (ctDNA) glioma. The methods used to detect ctDNA gliomas using samples including blood cerebrospinal fluid (CSF) detection techniques ctDNA, droplet digital PCR (ddPCR) next-generation sequencing (NGS), were discussed. Detection from plasma tumors challenging because blood–brain barrier (BBB). CSF been proposed as a medium analysis tumors, mutation was less sensitive than sequencing. Moreover, ongoing relevant clinical studies summarized. Finally, discussed challenges, future directions

Language: Английский

Proteomics profiling of extracellular vesicle for identification of potential biomarkers in Alzheimer's disease: A comprehensive review DOI
Jinjin Pei, Chella Perumal Palanisamy,

Selvaraj Jayaraman

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102359 - 102359

Published: May 29, 2024

Language: Английский

Citations

8
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma DOI Open Access
Allison R. Valerius, Lauren M. Webb,

Anna Thomsen

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10570 - 10570

Published: Sept. 30, 2024

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand therapy improve outcomes patients GBM. In this review, we provide broad overview novel therapies that have recently completed or actively undergoing study clinical trials. These across medical, surgical, We additionally review methods for improving trial design

Language: Английский

Citations

5
GBM immunotherapy: Exploring molecular and clinical frontiers DOI
Mrinal K. Ghosh,

Sunny Kumar,

Sabana Begam

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 356, P. 123018 - 123018

Published: Aug. 28, 2024

Language: Английский

Citations

4
Leptomeningeal Disease: Current Approaches and Future Directions DOI Creative Commons
Uğur Sener, Jessica Wilcox, Adrienne Boire

et al.

Current Neurology and Neuroscience Reports, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 18, 2025

Abstract Purpose of Review Leptomeningeal disease (LMD), or spread cancer cells into the pia and arachnoid membranes encasing brain spinal cord, is associated with high symptom burden poor survival at 2 to 5 months. Conventional treatments including photon-based radiation therapy, systemic chemotherapy, intrathecal chemotherapy demonstrate limited efficacy. Despite significant successes for a range solid tumors, immunotherapy has not yet demonstrated efficacy in management LMD. Advances understanding LMD pathophysiology, improved diagnostics, novel therapeutics are shifting this paradigm. In article, we review diagnostic treatment challenges Recent Findings We discuss use cerebrospinal fluid (CSF) analysis techniques such as circulating tumor cell CSF cell-free DNA assessment overcome limitations conventional modalities. then advances clinical trial data demonstrating proton craniospinal treat entire neuroaxis. emerging regarding targeted conferring durable benefit. Summary Novel combinatorial approaches will likely further improve outcomes patients

Language: Английский

Citations

0
Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand? DOI Open Access
Patricia Giuliani,

Chiara Simone,

Giorgia Febo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 9778 - 9778

Published: Sept. 10, 2024

Like most tumors, glioblastoma multiforme (GBM), the deadliest brain tumor in human adulthood, releases extracellular vesicles (EVs). Their content, reflecting that of origin, can be donated to nearby and distant cells which, by acquiring it, become more aggressive. Therefore, study EV-transported molecules has very important. Particular attention been paid EV proteins uncover new GBM biomarkers potential druggable targets. Proteomic studies have mainly performed “bottom-up” mass spectrometry (MS) analysis EVs isolated different procedures from conditioned media cultured biological fluids patients. Although a great number dysregulated identified, translation these findings into clinics remains elusive, probably due multiple factors, including lack standardized for isolation/characterization their proteome. Thus, it is time change research strategies adopting, addition harmonized selection techniques, MS methods aimed at identifying selected tumoral protein mutations and/or isoforms post-translational modifications, which deeply influence behavior. Hopefully, data integrated with those other “omics” disciplines will lead discovery pathways novel therapies.

Language: Английский

Citations

0
Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma DOI Creative Commons
Ying Lu, Zhouyu Wang,

Danmeng Zhang

et al.

Cellular and Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 18, 2024

Glioma is the most common primary malignant brain tumor. Despite significant advances in past decade understanding molecular pathogenesis of this tumor and exploring therapeutic strategies, prognosis patients with glioma remains poor. Accurate diagnosis very important for treatment prognosis. Although gold-standard method prediction tissue biopsy, it still has many limitations. Liquid biopsy can provide information on auxiliary gliomas. In review, we summarized application cell-free DNA (cfDNA) circulating (ctDNA) glioma. The methods used to detect ctDNA gliomas using samples including blood cerebrospinal fluid (CSF) detection techniques ctDNA, droplet digital PCR (ddPCR) next-generation sequencing (NGS), were discussed. Detection from plasma tumors challenging because blood–brain barrier (BBB). CSF been proposed as a medium analysis tumors, mutation was less sensitive than sequencing. Moreover, ongoing relevant clinical studies summarized. Finally, discussed challenges, future directions

Language: Английский

Citations

0